Drugs / Glucopyranosyl Lipid Adjuvant-Stable Emulsion
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03856996 Background | May 2019 → Mar 2021 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glucopyranosyl Lipid Adjuvant-Stable Emulsion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03856996 ↗ |
| Known as | GLA-SE | “Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE)” NCT03856996 ↗ |
| Action | Activate | “GLA-SE adjuvant, a TL4 agonist” PMID 39671174 ↗ Apr 2025 |
| Modality | Other / unclassified | “GLA-SE adjuvant” PMID 39671174 ↗ Apr 2025 |
| Route | Intramuscular | “for IM injection in the deltoid of the non-dominant arm” NCT03856996 ↗ |